Summary
Promedior, Inc. (Promedior) is a biotechnology company that develops therapeutic products for the treatment of fibrotic disorders and diseases. The company offers products under clinical development include PRM-151 and PRM-167. Promedior’s products are used in the treatment of idiopathic pulmonary fibrosis, myelofibrosis, systemic fibrotic diseases, age-related macular degeneration and retinal fibrovascular diseases. The company’s PRM-151 is a recombinant form of human pentraxin-2 protein (rhPTX-2) that is formulated for intravenous injection. Its PRM-167 drug is developed for intravitreal delivery in retinal fibrovascular diseases. The company also develops formulation of Pentraxin-2 therapeutics for inhaled local delivery in lung diseases. Promedior is headquartered in Lexington, Massachusetts, the US.
Promedior, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Promedior, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Promedior, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Promedior, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Promedior, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Promedior, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Promedior, Inc., Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Promedior Raises US$24.5 Million In Series D Financing 10
Promedior Secures US$6.5 Million In Venture Financing 12
Promedior Secures US$12 Million In Series C Financing Round 13
Acquisition 15
Bristol-Myers Squibb Enters into Option to Acquire Promedior and PRM-151 for up to USD1.25 Billion 15
Promedior, Inc. - Key Competitors 17
Key Employees 18
Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20
List of Tables
Promedior, Inc., Pharmaceuticals & Healthcare, Key Facts 1
Promedior, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Promedior, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Promedior, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Promedior, Inc., Deals By Therapy Area, 2010 to YTD 2016 8
Promedior, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Promedior Raises US$24.5 Million In Series D Financing 10
Promedior Secures US$6.5 Million In Venture Financing 12
Promedior Secures US$12 Million In Series C Financing Round 13
Bristol-Myers Squibb Enters into Option to Acquire Promedior and PRM-151 for up to USD1.25 Billion 15
Promedior, Inc., Key Competitors 17
Promedior, Inc., Key Employees 18
List of Figures
Promedior, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Promedior, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Promedior, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Promedior, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Promedior, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Promedior, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Promedior, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Promedior, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8